Company Onconova Therapeutics Inc Nasdaq
Equities
US68232V3069
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oncology Therapeutics
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -.--% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -.--% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 18/01/15 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 31/08/13 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23/10/23 |
Victor Moyo
CTO | Chief Tech/Sci/R&D Officer | - | 23/10/23 |
Matthew Parris
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 30/06/15 |
Jack Stover
BRD | Director/Board Member | 69 | 22/05/16 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 31/03/20 |
Steven Fruchtman
PSD | President | 73 | 18/01/15 |
Trafford Clarke
BRD | Director/Board Member | 66 | 18/12/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 25,301,009 | 21,604,002 ( 85.39 %) | 0 | 85.39 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+23.79% | 47.02B | |
+49.67% | 41.86B | |
+0.34% | 41.76B | |
-4.27% | 28.8B | |
+12.60% | 26.05B | |
-21.45% | 19.15B | |
+4.00% | 12.55B | |
+31.40% | 12.34B | |
-4.25% | 11.82B |